Cu- and Zn-AMSs immunoadjuvants enhanced cellular uptake of cancer model antigens into THP-1-differentiated macrophage-like cells, enhanced population of CD4+ and CD8+ T cells, promoted secretion of Th1 cytokines, evoked strong Th1 immune response, and inhibited EG7-OVA tumor growth (Fig. 1) compared with that of pristine γ-AlOOH mesostrands. This evidence concerns the gene CD8A and cancer.